Chronic Kidney Disease News

The FDA has granted approval to Elfabrio, manufactured by Chiesi Global Rare Diseases and Protalix BioTherapeutics Inc. The drug is intended to treat Fabry disease in adults, according to the press release.

AUSTIN, Texas — Despite the significant impact that kidney disease and its treatments can have on women’s health, patients admitted knowing very little about it, according to a presenter at the National Kidney Foundation Spring Clinical Meetings.

Kidney disease does not influence the benefits of the SGLT2 inhibitor empagliflozin on major HF events, even in patients at high renal risk, according to a new analysis of the EMPEROR-Pooled study.

SEATTLE — Higher post-dexamethasone cortisol was associated with lower estimated glomerular filtration rate independent of cardiovascular risk factors, researchers reported at the AACE Annual Scientific and Clinical Conference.

SEATTLE — Providers treating people with type 2 diabetes should take a complication-centric approach for determining first-line pharmacotherapy, according to a consensus statement.

SEATTLE — The rate of deaths attributed to vascular complications increased from 2001 to 2020 for adults with diabetes in the U.S., with the rise mainly due to an increase in deaths from diabetic nephropathy, according to a speaker.

DESTIN, Fla. — Hydroxychloroquine remains one of the most important drugs in lupus management and should be used as background therapy in nearly all cases, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

The FDA has granted fast-track designation to CABA-201, a CD19-CAR T cell investigational therapy, for the treatment of systemic lupus erythematous and lupus nephritis, according to a press release from the manufacturer.

Patients who experience AKI during hospitalization showed an increased risk for 90- and 365-day all-cause and selected-cause rehospitalization and death following discharge, according to data in the American Journal of Kidney Diseases.

Patients who experience AKI during hospitalization showed an increased risk for 90- and 365-day all-cause and selected-cause rehospitalization and death following discharge, according to data in the American Journal of Kidney Diseases.